Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Data confirm the positive topline results announced in December 2021 demonstrating AL001 in plasma is bioequivalent to the marketed lithium carbonate product Results show that the shapes of the lithium plasma concentration versus time curves are similar to marketed product ATLANTA–(BUSINESS WIRE)– Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel […]
Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease
TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (Nasdaq: ALZN) (“Alzamend”), a preclinical stage biopharmaceutical company, today announced that it submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021. The Phase 1, first-in-human study is for the purpose of […]
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million
Tampa, FL – (Business Newswire – June 17, 2021) – Alzamend Neuro, Inc. (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the closing of its initial public offering of 2,500,000 shares of its common stock and full exercise of the underwriter’s […]
Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease
Cocrystal Lithium-Based Therapy, “LiProSal™” Targets the Reduction of Agitation in Patients with AD Salt Lake City, UT – (Globe Newswire – October 29, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”) that, together, comprise the basis for a therapy […]
Alzamend Neuro Announces Pricing of Initial Public Offering
TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro, Inc. (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the pricing of its initial public offering of 2,500,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from […]
